ClinicalTrials.gg

Program

MG1111

A development code. Also written as “MG1111 (Barycela inj.)” and “MG1111 (BARICELA)”.

Its studies are mostly in Chickenpox, led by GC Biopharma.

Furthest: phase 3, since Jul 7, 20254 company-led studies, 2 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GC Biopharma42 open or runningphase 3since Jul 7, 2025Feb 12, 2015Aug 2027phase 3 · NCT07054099

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 12, 2015First study: phase 1 study in ChickenpoxFirst studyNCT02367638 · 39 enrolled
  2. May 24, 2022Phase 2 study in ChickenpoxNCT05422508 · 230 planned · Korea, Republic of
  3. Dec 2, 2022No phase study in Varicella Zoster Virus InfectionNCT05664152 · 250 enrolled
  4. Jul 7, 2025Phase 3 study in ChickenpoxNCT07054099 · 474 planned · Thailand

Ahead

  1. Aug 2027Primary completion: phase 3 study in ChickenpoxNCT07054099

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07054099Chickenpox · Thailand3RecruitingAug 2027474
NCT05664152Varicella Zoster Virus Infection–UNKNOWNApr 2023250
NCT05422508Chickenpox · Korea, Republic of2RecruitingJun 2025230
NCT02367638Chickenpox1CompletedJul 201539

How it is read

Names in the registry

  • “MG1111”, 2 entries
  • “MG1111 (Barycela inj.)”, 1 entry
  • “MG1111 (BARICELA)”, 1 entry

Codes read as this program: MG1111.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.